Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 2 2Phase 1/2 1Phase 1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1

Conditions

Breast Neoplasms 76Carcinoma, Non-Small-Cell Lung 73Multiple Myeloma 58Prostatic Neoplasms 57Colorectal Neoplasms 45Leukemia, Myeloid, Acute 43Neoplasms 41Melanoma 35Lymphoma 35Lung Neoplasms 32Ovarian Neoplasms 31Lymphoma, Non-Hodgkin 30Squamous Cell Carcinoma of Head and Neck 29Sarcoma 28Neoplasm Metastasis 27Pancreatic Neoplasms 26Endometrial Neoplasms 25Carcinoma, Hepatocellular 25Hodgkin Disease 23Carcinoma, Renal Cell 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Lymphoma, Large B-Cell, Diffuse 22Leukemia, Lymphocytic, Chronic, B-Cell 22Glioma 22Recurrence 21Urinary Bladder Neoplasms 20Myelodysplastic Syndromes 20Head and Neck Neoplasms 20Esophageal Neoplasms 17Stomach Neoplasms 16

Interventions

liposomal doxorubicin 1Zidovudine 1Vincristine 1Valganciclovir 1Sirolimus 1Rituximab 1Prednisone 1Interferon-alpha 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × HIV Infections × 30 days × Clear all
NCT00092222 2026-06-05

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
75 enrolled
Lymphoid

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

NCT07545746 2026-06-02

ASCEND

UNC Lineberger Comprehensive Cancer Center

Phase 2 Not yet recruiting
140 enrolled
Gynecologic

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, HIV Infections, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡